Sea Buckthorn for Vaginal Dryness: Capsules, Gel and Suppositories Compared

Before buying sea buckthorn for vaginal dryness, identify what the advertised study actually tested. Swallowed oil, a vaginal gel containing several ingredients and a suppository used before colposcopy are three different interventions.

The most useful comparison is whether women felt better than those receiving placebo. A change in tissue appearance or a satisfaction percentage cannot supply that answer on its own.

The older capsule trial found a tissue benefit, without better symptom relief

The Finnish trial randomized 116 postmenopausal women aged 55–75; 98 completed three months. It tested 3 g daily of a standardized berry-and-seed oil blend against placebo oil.¹

A clinician-rated measure of epithelial integrity improved in 36% versus 16% of participants with available measurements. The overall vaginal health index difference was not statistically significant, nor were improvements in reported dryness, burning or itching. Vaginal pH and a paper-strip moisture test also showed no significant benefit.¹

That is a narrower finding than “capsules relieve vaginal dryness.” The study tested numerous outcomes without adjustment for multiple testing and excluded missing measurements. Aromtech, the oil manufacturer, co-funded it; the first author was an employee.¹

The newer oral trial also needs its placebo comparison

The 2024 study² assigned 40 women over 45, 20 per group, to an Omegia softgel or placebo for 12 weeks. Its methods specify 500 mg of sea buckthorn oil daily. Participants were recruited as healthy volunteers, rather than specifically for confirmed menopause-related vaginal atrophy.²

Vaginal symptom scores improved within the supplement group. However, the report explicitly states that vaginal improvements did not reach statistical significance against placebo. Table 10 gives P = 0.484 for the between-group dryness comparison. The separate finding that 65% were satisfied or very satisfied with dryness improvement is not a placebo-adjusted response rate.²

Puredia supplied the oil and helped fund the research; three authors listed company affiliations. The paper also contains inconsistent dose wording elsewhere, another reason not to use it to choose a supplement dose.²

A positive gel trial tested five ingredients together

A 2021 trial³ randomized 60 postmenopausal women to Meclon Idra vaginal gel or placebo. The formula combined sea buckthorn oil with aloe vera, 18β-glycyrrhetic acid, hyaluronic acid and glycogen. Over approximately 12 weeks, it improved vaginal dryness and other symptoms compared with placebo.³

The trial supports investigating that complete local formula. It cannot identify sea buckthorn’s individual contribution or establish that swallowing oil produces the same result. Four placebo participants were lost at the last follow-up. Alfasigma funded the study. Two participants reported severe vaginal burning and itching after the active product; these resolved without medication.³

The 2025 suppository study was about preparing for colposcopy

Researchers in Shanghai assigned 377 postmenopausal patients to no pretreatment, a compound sea buckthorn suppository or estrogen ointment. Treatment lasted two weeks before colposcopy, an examination of the cervix and vagina after abnormal screening findings. Colposcopy results were analyzed for 368 patients.⁴

Both treated groups had better examination adequacy than the untreated group. The suppository contained other ingredients, including matrine, calamine and borneol. Examiners could often identify treatment from residue, so assessment was not masked. Six suppository recipients stopped medication because of discomfort.⁴

The absence of a significant difference from estrogen does not establish equivalence. This was a short preparation study, without a prespecified non-inferiority analysis or a long-term dryness-treatment comparison. It cannot substantiate an oral supplement claim.⁴

Use the symptom you want treated to choose the next step

For menopause-related genitourinary symptoms, current UK NICE⁵ guidance offers vaginal estrogen to people without a breast cancer history. It also supports non-hormonal vaginal moisturisers or lubricants when estrogen is contraindicated or unwanted, and their use alongside vaginal estrogen.⁵

After breast cancer, NICE⁵ recommends non-hormonal moisturisers or lubricants first. Symptoms persisting during aromatase-inhibitor treatment warrant discussion with a breast cancer specialist. The sea buckthorn studies above do not show that sea buckthorn is safe during cancer treatment.⁵

If you are weighing a supplement, bring the exact formula and daily amount to the discussion. Specify the intended result: less dryness between sexual activity, less burning or less pain with penetration. Ask what evidence supports that outcome and when to review whether treatment is helping. Buying a product with the same plant name does not reproduce a trial’s formula or route of administration.

The NHS⁶ advises assessment when dryness persists for a few weeks despite self-care, affects daily life or comes with unusual discharge or bleeding. It recommends products designed for vaginal use. A capsule intended for swallowing should not become a homemade vaginal treatment.⁶

Chapter 8, “Dry Spells,” in Down There, Decoded separates lubricant used around sexual activity from moisturiser used for ongoing dryness, then discusses prescription options. Use those distinctions to describe what is bothering you before deciding whether another bottle belongs in the plan.